Beatriz Sánchez Moreno

Dr. Beatriz Sánchez Moreno


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EREmilia Roy-Vallejo
Emilia Roy-Vallejo
APAquilino Sánchez Purificación
Aquilino Sánchez Purificación
JTJose David Torres-Peña
Jose David Torres-Peña
BMBeatriz Sánchez Moreno
Beatriz Sánchez Moreno
FAFrancisco Arnalich
Francisco Arnalich
ONOn Behalf Of The Semi-Covid-19 Network
On Behalf Of The Semi-Covid-19 Network
Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63–0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62–0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.

1 October 2023 in Journal of Intellectual Disability Research
Verified
Journal Article
Open access
BMBeatriz Sánchez Moreno
Beatriz Sánchez Moreno
LALaura Adán‐Lirola
Laura Adán‐Lirola
JRJavier Rubio‐Serrano
Javier Rubio‐Serrano
DADiego Real de Asúa
Diego Real de Asúa
Background: The life expectancy of people with Down syndrome (DS) is limited by Alzheimer's disease (AD)‐related deaths, mainly due to respiratory infections. The emergence of the COVID‐19 pandemic could have changed known, past trends in mortality in this population. We analysed the differences in causes of mortality between individuals with DS deceased before and after the onset of the pandemic.Method: This is a cross‐sectional study of adults with DS recruited at a tertiary, university outpatient clinic in Madrid, Spain. Demographic and clinical data were retrospectively collected from their medical records, including information on their deaths, if any.Results: Five hundred seventy‐two adults were included in the study, and 67 (11.7%) died. The main cause of death was respiratory infections, which occurred in 36 participants [9 (45.0%) before, and 27 (58.7%) after the appearance of COVID‐19]. No significant differences were found in the determinants of pre‐pandemic and post‐pandemic death after adjusting for age and AD, except for an association between the use of psychotropic medication and death in the post‐pandemic period (odds ratio: 2.24; 95% confidence interval: 1.04–4.82). Vaccination against COVID‐19 showed a marked protective effect against mortality (odds ratio: 0.0002; 95% confidence interval: 6.7e10−6 to 0.004).Conclusions: The appearance of COVID‐19 has not impacted the overall trend of increase in mean age of death of adults with DS in our milieu, probably thanks to the very important protective effect of vaccination, which supports prioritising people with DS in future immunisation campaigns. The association between psychotropic medication use and mortality requires further exploration.

5 August 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
BMBeatriz Sánchez Moreno
Beatriz Sánchez Moreno
LZLinda Zhang
Linda Zhang
ASAna Carril Salaberry
Ana Carril Salaberry
MRMateus Rozalem‐Aranha
Mateus Rozalem‐Aranha
FMFernando Moldenhauer
Fernando Moldenhauer
BSBryan A. Strange
Bryan A. Strange
BACKGROUND: To compare the performance of computed tomography (CT) with that of magnetic resonance imaging (MRI) in assessing brain atrophy in Down syndrome (DS).METHODS: Retrospective comparison of CT‐derived gray and white matter measurements with those obtained by MRI using voxel‐based morphometry (VBM) in adults with DS who underwent both scanning modalities with a maximum interval of 1 year. The concordance of both tests was compared across sample quartiles.RESULTS: Eleven of 23 participants had some degree of cognitive decline. When comparing VBM outputs of both imaging techniques, an overlap of voxels negatively correlated with dementia severity was observed in the right temporal lobe. Observed agreement was 92.3% (quadratic‐weighted kappa index 0.71) for both gray and white matter.DISCUSSION: CT and MRI analyses showed a similar decrease in brain volume as cognitive decline increased. Our results highlight the potential use of CT in computational neuroanatomy studies of DS.Highlights: Voxel‐based morphometry shows that computed tomography (CT) and magnetic resonance imaging (MRI) yield similar brain atrophy patterns in DS. Strong agreement (kappa index 0.71) was found between CT and MRI assessments. CT‐identified right temporal lobe volume loss linked to cognitive decline in DS. CT offers a practical, accessible alternative to MRI for brain imaging in DS. Artificial intelligence–based CT analysis enhances neuroimaging for DS with reduced motion issues.

25 February 2021 in medRxiv
Verified
Preprint
Open access
PDF file
EREmilia Roy-Vallejo
Emilia Roy-Vallejo
APAquilino Sánchez Purificación
Aquilino Sánchez Purificación
JPJosé David Torres Peña
José David Torres Peña
BMBeatriz Sánchez Moreno
Beatriz Sánchez Moreno
FAFrancisco Arnalich
Francisco Arnalich
JNJesús Millán Núñez-Cortés
Jesús Millán Núñez-Cortés
Background: The use of ACEI (Angiotensin-Converting Enzyme Inhibitor) and ARB (Angiotensin II Receptor Blocker) in COVID-19 remains controversial. Our main aim was to describe the effect of ACEI/ARB treatment during COVID-19 hospitalization on mortality and complications. Methods: Retrospective, observational, multicenter study, part of the SEMI-COVID-19 Registry, comparing patients with COVID-19 treated with ACEI/ARB during hospitalization to those not treated. The primary endpoint was incidence of the composite outcome of prognosis (IMV [Invasive Mechanical Ventilation], NIMV [Non-Invasive Mechanical Ventilation], ICU admission [Intensive Care Unit], and/or all-cause mortality). The secondary endpoint was incidence of MACE (Major Adverse Cardiovascular Events). We evaluated both outcomes in patients whose treatment with ACEI/ARB continued or was withdrawn during hospitalization. Results: Between February and June 2020, 11,205 patients were included, with mean age 67 years (SD=16.3) and 43.1% female; 2,162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed a protective effect on all-cause mortality ( p <.0001). In hypertensive patients it was also protective in terms of IMV, ICU admission, and the composite outcome of prognosis ( p <.0001 for all). No differences were found in incidence of MACE. Patients previously treated with ACEI/ARB who continued treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63-0.76). ARB had a more beneficial effect on survival than ACEI (HR 0.77, 95%CI 0.62-0.96). Conclusion: ACEI/ARB treatment during COVID-19 hospitalization had a protective effect on mortality. The benefits were greater in hypertensive patients, those who continued treatment during hospitalization, and those taking ARB. Summary: Treatment with ACEI/ARB during COVID-19 hospitalization showed a beneficial effect on mortality in the general population. The benefit was greater in hypertensive patients, in those who maintained treatment during hospitalization and those taking ARB.